Metastatic Renal Cell Carcinoma Management

Flavio L. Heldwein, Bernard Escudier, Gordon Smyth, Carlos A. V. Souto, Guy Vallancien

Department of Urology, Institut Mutualiste Montsouris (FLH, BE, GS, GV), Université Rene Descartes, Paris V, Paris, France; Division of Urology, Santa Casa Hospital (CAVS), Porto Alegre, Brazil

ABSTRACT

Purpose: To assess the current treatment of metastatic renal cell carcinoma, focusing on medical treatment options.

Material and Methods: The most important recent publications have been selected after a literature search employing PubMed using the search terms: advanced and metastatic renal cell carcinoma, anti-angiogenesis drugs and systemic therapy; also significant meeting abstracts were consulted.

Results: Progress in understanding the molecular basis of renal cell carcinoma, especially related to genetics and angiogenesis, has been achieved mainly through the study of von Hippel-Lindau disease. A great variety of active agents have been developed and tested in metastatic renal cell carcinoma (mRCC) patients. New specific molecular therapies in metastatic disease are discussed. Sunitinib, Sorafenib and Bevacizumab increase the progression-free survival when compared to therapy with cytokines. Temsirolimus increases overall survival in high-risk patients. Growth factors and regulatory enzymes, such as carbonic anhydrase IX may be targets for future therapies.

Conclusions: A broader knowledge of clear cell carcinoma molecular biology has permitted the beginning of a new era in mRCC therapy. Benefits of these novel agents in terms of progression-free and overall survival have been observed in patients with mRCC, and, in many cases, have become the standard of care. Sunitinib is now considered the new reference first-line treatment for mRCC. Despite all the progress in recent years, complete responses are still very rare. Currently, many important issues regarding the use of these agents in the management of metastatic renal cancer still need to be properly addressed.

Key words: renal cell carcinoma; neoplasm metastasis; anti angiogenic agents; therapy

INTRODUCTION

Kidney cancer is responsible for more than 100,000 deaths per year (1). Renal cell carcinoma (RCC) remains one of the greatest challenges of urological oncology and is the third leading cause of death in genitourinary cancers. For unclear reasons, since the fifties, the annual incidence has risen by approximately 130%. According to the U.S. Surveillance, Epidemiology and End-Results statistics, 45% of these tumors have been diagnosed as locally advanced or metastatic disease and the two-year survival rates varies between 0 to 20% (2).

During the past decades, immunotherapies with cytokines based on interferon alpha (IFN-alpha) and interleukin-2 (IL2) have been the standard therapies for mRCC. Results with these standard therapies have been poor and with significant toxicities. Results with chemotherapy and hormonal agents have likewise been disappointing.

The usefulness of newer targeted therapies has been demonstrated in other malignancies such as gastro-intestinal stromal and colonic tumors, as well as leukemia. These therapies are directed at specific molecular targets implicated in angiogenesis and tumor proliferation. These encouraging results, coupled
with a fuller understanding of molecular pathways in RCC have paved the way for new targets in the treatment of kidney cancer.

TREATMENT OF METASTATIC DISEASE

Conventionally, the following therapeutic modalities are available for patients with mRCC.

Nephrectomy and/or Metastasectomy Alone

Nephrectomy can improve quality of life and may, although rarely, induce spontaneous regression of metastases (0.7%). If the metastases are resectable, nephrectomy with metastasectomy is the best treatment option for disseminated renal cell carcinoma. This, however, is applicable to less than 2-3% of patients and may be associated with significant perioperative morbidity and mortality (3).

Metastasectomy has provided a five-year survival rate of 25-60% for pulmonary metastases, 13-30% for a single osseous lesion, 50-75% for local recurrences. Regarding metastasectomies in cerebral lesions, if complete resection can be achieved, the 5-year survival rate can be doubled when compared to observation, 13.8% vs. 7% respectively (4,5). Advantages have been demonstrated when hepatectomy was performed in patients with single hepatic lesions (4).

Neoadjuvant Cytoreductive Surgery and Immunotherapy

Radical nephrectomy prolongs survival in metastatic patients when combined with cytokine therapy (6-8). This approach offers some theoretical advantages, such as prevention of complications during systemic treatment, reduction of tumor immunosuppressive potential, removal of the primary source of growth factors and providing tumor cells for analysis and experimental therapies. Non-randomized studies have demonstrated objective complete responses in 12.6% and partial responses of 39% (9).

The European Organization for Research and Treatment of Cancer has reported a trial (EORTC 30947) where patients with mRCC were randomized to IFN-alpha or INF-alpha plus radical nephrectomy. In the group submitted to radical nephrectomy, the overall survival increased from 7 to 17 months (6). Also, in the early 2000’s, Flanigan et al. (Southwest Oncology Group Trial 8949) randomly investigated surgery followed by IFN-alpha vs. IFN-alpha alone, and also found a longer median survival in the combination arm (11.1 vs. 8.1 months; p = 0.05) (7).

Therefore, the standard of care in the immunotherapy era was cytoreductive nephrectomy prior to immunotherapy. Whether nephrectomy will be required in the new era of targeted therapy remains unclear and awaits clarification in future trials. Laparoscopic cytoreductive nephrectomy may serve to decrease the postoperative recovery time and therefore allow earlier initiation of systemic therapy.

Initial Systemic Therapy Followed by Nephrectomy in Responders

It seems logical to suppose that in patients who respond favorably to initial systemic therapy, cytoreductive nephrectomy would be beneficial. Benefits could include the possibility of down-staging the tumor and the sparing of the morbidity of surgery in the non-responders. However, there is a lack of evidence to support this approach, although survival results are promising (10,11). There exist no reported data regarding the optimal timing of surgery or whether the morbidity of a later procedure is increased.

Immunotherapy Alone

Several controlled trials concerning immunotherapy in metastatic renal cell carcinoma (mRCC) have shown response rates of 2-39% (12). However, in the majority of these trials, the patients had undergone nephrectomy before any evidence of clinical metastases, therefore the option of “immunotherapy alone” remains incompletely evaluated.

Cytokines

Treatments that combine chemotherapy and hormonal agents have had modest clinical benefits (5-10%). However, immunotherapy produced objective
Metastatic Renal Cell Carcinoma Management

response rates in the range of 10-20% with median stable disease (SD) of 3-16 months (13).

The clinical use of Interferon (IFN)-alpha and Interleukin(IL)-2 was extensively studied in the last decade and considered the first-line strategy in the treatment of mRCC. IL-2 was discovered in 1976 and described as a protein that promotes “in vitro” T cell growth.

A Cochrane review and a meta-analysis confirmed the value of IFN-alpha in mRCC. IFN-alpha provides response rates of 10-15% and complete responses in 1-2%, however durable responders were rare (14,15). Randomized trials comparing hormonal therapy and IFN resulted in a reduction of death risk of 28% in the IFN arm. The IFN group showed an improvement of 2.5 months in overall survival. Similar results were found when IFN was compared to chemotherapy (16).

Despite the low response rate to IFN, a significant improvement in survival was evident. Such benefit is now questionable, because it could be due to disease stabilization, which may occur in a great number of patients. Carbonic anhydrase IX (CA IX) expression may play a strategic role tumor progression or stabilization. Previous investigations have demonstrated that RCC without Von-Hipple Lindau (VHL) mutation showed lower CAIX expression and this is invariably associated with a highest malignant potential (17). Other biomarkers may also be of interest, such as levels of vascular endothelial growth factor (VEGF) and VEGFR subtypes and COX2 expression.

High dose intravenous IL2 can produce a complete response (CR) in selected patient cohorts. In a non-randomized trial, approximately 9% of patients obtained a CR and 70-80% maintained a prolonged response (17). IL2 and IFN have been shown to improve response rate and progression-free survival in a large randomized trial and may represent a good treatment option. Cytokine therapies have significant toxicity and IV regimens require intensive care but until recently they were the only treatment strategy available in mRCC.

New Target-Therapies for Metastatic-RCC

Von-Hippel-Lindau Disease (VHL) and Molecular Targets

In 1904, the German ophthalmologist Eugene Von Hippel reported a case of retinal angioma. Twenty years later, the Swedish pathologist Arvid Lindau described a central nervous system hemangioblastoma. However, it was only in 1928, that Cushing and Bailey described the syndrome. VHL affects approximately 1 in 35000 individuals. VHL is an autosomal dominant disease, whose genetic defect is located in chromosome 3p25-26 (18). The clinical manifestations are a variety of tumors in the retina, cerebellum, spinal cord, epididymis, pancreas, adrenals and kidneys. The VHL gene is highly preserved and present from insects to mammals, indicating biological importance in homeostasis.

Mutations of VHL gene are described in almost 100% of familial RCC. The incidence of RCC in VHL patients is 24-45% and they are all of the clear cell variety.

Also, VHL gene is often mutated in sporadic RCC and VHL disease molecular scheme serves as model for understanding the action mechanism of the new anti-angiogenic drugs. Inactivation of the VHL tumor suppressor gene induces a hyper-expression of genes regulated by hypoxia, including vascular endothelium grown factor (VEGF), platelet-derived growth factor (PDGF) among others (Table-1) (Figure-1).

Probably, the VHL mutation in RCC is an early event, because 80% of T1, low grade (G1-G2) and incidental tumors express such mutation. Therefore, other molecular routes are likely involved in RCC angiogenesis (19).

A better understanding of tumoral angiogenesis and the multiple signal routes implicated in renal cancer progression, have resulted in clinical use and in recent approval by European (EMEA) and US Agencies (FDA) of anti-angiogenic drugs for treat mRCC.

At least 5 emerging anti-angiogenic drugs are being intensively investigated. Initially, these drugs were investigated as second-line treatments in metastatic disease. Results have been promising and phase III trials were and are being conducted. A great number of trials are open, to study using them as first-line monotherapy or in horizontal and vertical combinations (Table-2).

However, there has been criticism of the current way to determine tumor response to these new agents. Critics argue that the traditional criteria based only in tumor size changes, the Response Evaluation
Table 1 - Growth factors related to target therapies in renal cancer management.

<table>
<thead>
<tr>
<th>Growth Factors</th>
<th>Receptor</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF</td>
<td>VEGF</td>
<td>Activates the transcription of target genes that codify proteins as VEGF, PDGFR, TGF-alpha, EGF, erythropoietin.</td>
</tr>
<tr>
<td>Hypoxia inducible factor (subunits alpha and beta)</td>
<td>VEGFR</td>
<td>Most potent pro-angiogenic. Stimulates proliferation, metastases and inhibits apoptosis.</td>
</tr>
<tr>
<td>Vascular endothelial growth factor</td>
<td>PDGFR</td>
<td>Tumoral proliferation through induction of DNA synthesis, growth and apoptosis inhibition. Possibly a negative prognostic marker.</td>
</tr>
<tr>
<td>Platelet-derived growth factor</td>
<td>EGFR (ErbB-1, 2, 3 e4)</td>
<td>Stimulates VEGF production. Negative prognostic marker.</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
<td>CAIX</td>
<td>Regulates ions channels, pH, hypoxia conditions. Contributes to invasion and metastases.</td>
</tr>
<tr>
<td>Transforming growth factor alpha</td>
<td>ErbB-1</td>
<td>Induces angiogenesis and cell proliferation</td>
</tr>
<tr>
<td>Hepatocyte grown factor</td>
<td>MET</td>
<td>Implicated in survival and dissemination</td>
</tr>
</tbody>
</table>

Figure 1 – Molecular scheme of mechanism of action of von Hippel-Lindau protein (VHL). In conditions of hypoxia or VHL gene inactivation and consequently, absence of codified protein (pVHL), there is no formation of complex formed by the binding of hypoxia inducible factor (HIF) and hydroxyproline residue. Therefore, there is no HIF degradation, resulting in accumulation of HIF in nucleus and promoting oncogenesis, through super-expression of encoding genes implicated in: tumoral angiogenesis (vascular endothelial growth factor [VEGF]), glucose transport (GLUT1, GLUT3), glycolysis (fructose-6-kinase-2), pH control (carbonic anhydrase family, CA IX), endothelial proliferation (platelet-derived growth factor [PDGF], transforming growth factor-alpha [TGF-alpha]), erythropoietin (EPO), cellular migration (CXCR4) and apoptosis (Bid, Bax, Bax) (15).
### Table 2 – Novel target agents in management of metastatic renal cell carcinoma.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Molecular Target</th>
<th>Action and Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VEGF Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Monoclonal antibody</td>
<td>VEGF</td>
</tr>
<tr>
<td>VEGF Trap</td>
<td></td>
<td>VEGF</td>
</tr>
<tr>
<td><strong>Tyrosine-kinases Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorafenib (BAY 43-9006)</td>
<td>Multi-tyrosine kinases inhibitor</td>
<td>C-RAF, B-RAF, <em>KIT</em>, VEGFR-2, VEGFR-3, PDGFR-beta†</td>
</tr>
<tr>
<td>Sunitinib (SU 11248)</td>
<td>Multi-tyrosine kinases receptors inhibitor</td>
<td>KIT, FLT-3, RET*, PDGFR, VEGFR 1, 2 e 3</td>
</tr>
<tr>
<td>Vatalanib (PTK787/ZK222584)</td>
<td>TK receptors inhibitor</td>
<td>VEGFR 1 and 2, PDGFR</td>
</tr>
<tr>
<td>Axitinib (AG-013736)</td>
<td>TK receptors inhibitor</td>
<td>VEGFR-1, 2 and 3, PDGFR-beta</td>
</tr>
<tr>
<td>Pazopanib (GW786034)</td>
<td>Multi-tyrosine kinases inhibitor</td>
<td>KIT</td>
</tr>
<tr>
<td>Imatinib (XL 880)</td>
<td>TK inhibitor</td>
<td>PDGFR, VEGFR 1, 2 and 3, PDGFR-alpha and beta</td>
</tr>
<tr>
<td><strong>EGF Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lapatinib (GW572016)</td>
<td>Selective inhibitor</td>
<td>EGFR (ErbB2)</td>
</tr>
<tr>
<td>Gefitinib (ZD1839)</td>
<td>Selective inhibitor</td>
<td>EGFR (ErbB2)</td>
</tr>
<tr>
<td>Erlotinib (OSI-774)</td>
<td>Selective inhibitor</td>
<td>HER1/EGFR TK</td>
</tr>
<tr>
<td><strong>m-TOR Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temsirolimus (CCI-779)</td>
<td>Selective inhibitor</td>
<td>m-TOR**</td>
</tr>
<tr>
<td>Everolimus (RAD-001)</td>
<td>Selective inhibitor</td>
<td>m-TOR</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bortezomib (OS-341)</td>
<td>HIF inhibitor</td>
<td>Proteossoms</td>
</tr>
<tr>
<td>Velociximab</td>
<td>Anti-integrin antibody</td>
<td>alpha5beta1</td>
</tr>
<tr>
<td>G250 (WX-G250)</td>
<td>Selective inhibitor</td>
<td>CAIX**</td>
</tr>
</tbody>
</table>

* = C-RAF, B-RAF - serine/threonine kinase isoforms; † = KIT - stem cell factor receptor; ‡ = VEGFR-2, VEGFR-3 – vascular endothelial growth factor receptors; § = PDGFR, PDGFR-beta - plaquet-derived growth factor receptors; || = FLT-3 – tyrosine kinase-3 Fms like; ¶ = RET - glial cell lineage derived neurotrofic factor; ** = m-TOR – mammalian target of rapamycin; †† = CAIX - carbonic anhydrase IX
Criteria in Solid Tumors (RECIST) probably is not the best way to determined if anti-angiogenic drugs works or not in clinical trials. Therefore, other endpoints, such as stable disease and progression-free survival should be considered to predict new agents' approval.

Based on pretreatment patient characteristics, independent prognostic indicators were identified in anti-angiogenic agents' trials and they are similar to those reported in cytokine era. Baseline risk factors that need to be considered in order to achieve the best possible outcome include time from diagnosis to treatment (if < 1 yr. vs. ≥ 1 yr.), age, performance status, RCC subtypes, site and size of metastases, symptoms, corrected calcium (20).

**Sunitinib Malate - SU11248 (Sutent® - Pfizer)**

Sunitinib is a small molecule, oral multitargeted tyrosine kinase inhibitor (TKI) whose target is several tyrosine-kinase receptors (TKR). Also, Sunitinib has an anti-tumoral action directly in some tumor cells and an anti-angiogenic action through selective inhibition of PDGFR-alpha and PDGFR-beta, VEGFR types 1 to 3, KIT and FLT3. Results of two phase II trials have been published, using Sunitinib as second-line therapy in mRCC refractory to cytokines (19,21). These studies included 63 and 106 patients, respectively. The treatment was designed with Sunitinib 50 mg/day for 4 weeks in repeated cycles to every 6 weeks. The principal adverse effects related were fatigue (38%, 28%), diarrhea (24%, 20%), nausea (19%, 13%) and stomatitis (19%, 14%). Laboratory abnormalities grade 3 and 4 (graduation in agreement with National Cancer Institute Common Terminology Criteria for Adverse Events - CTCAE, Version 3.0); such as neutropenia, anemia, thrombocytopenia and lipase increase were observed in 13% and 16%, 10% and 6%, 0% and 6%, and 21% and 17% in the two studies, respectively. The overall response rates were 40% and 44% and 3-months SD was achieved in 28% and 23% of the cases, respectively. In general, 66% of the patients had some clinical benefit. The progression-free survival (PFS) was 8.7 and 8.3 months, respectively, the median survival was 16.4 months in the first study, and it was not reported in the second.

Such response rates, measured by RECIST criteria, had not been observed in second-line treatments in the conventional immunotherapy era. Figure-2 shows an example of partial response with Sunitinib that is the new standard of care for mRCC.

A phase III trial comparing IFN-alpha and Sunitinib as first-line treatment for mRCC was recently completed. 750 patients were enrolled and randomized, 90% had undergone prior nephrectomy. The average PFS was longer in the Sunitinib group compared with the IFN group (11 vs. 5 months). Only one case of complete response was observed in Sunitinib group (22). Although not yet published, survival data analysis was orally presented in the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting showing a survival benefit in favor of Sunitinib (23).

Currently, a great number of trials are open, combining Sunitinib with Gefitinib, Bevacizumab, Gemcitabine, Capecitabine or Interferon. Caution is recommended in associating Sunitinib and cytochrome P450, CYP3A4 inhibitors or inducers. Cardiovascular safety remains unknown.

**Sorafenib Tosilato - BAY 43-9006 (Nexavar® - Bayer)**

Sorafenib is an oral multi-kinase inhibitor and it has an antitumoral activity in xenograft models of human RCC. Initially, it was presumed that Sorafenib acted by inhibiting serine/treonine Raf-1 kinase. Inhibitor activity against B-Raf and other TK receptors as VEGFR-2, PDGF-R, FLT-3 and c-kit were proven.

Two phase II trials have been reported and have described significant clinical benefits in metastatic patients (recommended dose as 400 mg orally twice daily). In one of these studies, 397 patients with several types of refractory solid tumors were included, of these, 89 patients had mRCC and SD was observed in 50% (24). In 2005, an interim analysis of a phase III trial were presented and final results published in 2007 (TARGET - Treatment Approaches in Renal Global Cancer Evaluation Trial), that compared Sorafenib and placebo in refractory metastatic patients (25). A dose modification was necessary in 25% of the patients who presented with adverse events. Treatment was discontinued in 38%, however, only 9% discontinued the treatment because of adverse effects. The more common side effects were skin rash
or desquamation (31%), diarrhea (30%), hand-foot skin syndrome (26%) and fatigue (18%). Hypertension (8%) and neuropathy (9%) were rarely observed. No significant hematological or biochemical toxicity was observed. Eighty percent of the patients showed a clinical benefit. In the Sorafenib group, a PR was achieved in just 2%, but SD was observed in 78%, while in the placebo arm there were no PR and SD was seen in 55%. The PFS was 24 weeks in the Sorafenib arm, against 12 weeks in the placebo arm (p < 0.000001). Because of this prolongation of the PFS, the protocol TARGET was modified, allowing patients in the placebo arm to be crossed-over for treatment with Sorafenib (Figure-3).

A phase II trial comparing first-line Sorafenib vs. IFN was presented at ASCO 2007 and there was no difference in PFS between both arms (26). Ryan et al. and SWOG presented a phase II trial, where Sorafenib was combined with IFN as first-line therapy. In 62 patients, PR was achieved in 19% and a PFS in 50% (27).

**Bevacizumab (Avastin® - Genentech - Roche)**

Bevacizumab is an anti-VEGF monoclonal humanized recombinant antibody (anti-VEGF MoAb) that recognizes all VEGF isoforms and has a prolonged half-life (17-21 days). Yang et al. first reported results of a randomized phase II study that compared patients with mRCC refractory to cytokine therapy. One hundred and sixteen patients were randomized into 3 groups: 40 patients to placebo, 37 to the Bevacizumab group at a dose of 3 mg/kg and 39 patients 10 mg/kg q2w. PFS (4.8 months) was increased significantly in high-dose Bevacizumab, compared with placebo (2.5 months) (p = 0.001) (28). The high-dose Bevacizumab group reached PR of 10%. The prob-
ability of PFS for patients that received this antibody in high-dose, low-dose and placebo were 64%, 39% and 20% in 4 months, and 30%, 14% and 5% to the 8 months, respectively. The study was interrupted after interim analysis because of the differences observed in PFS. Usually, the treatment was well tolerated: hypertension, malaise and proteinuria were the most common side effects.

Combinations between Bevacizumab and other drugs are currently under investigation. Although monotherapies targeted against epidermal grown factor receptor (EGFR) have yielded disappointing results, Hainsworth et al. published their results in 63 patients with metastatic RCC associating Bevacizumab 10 mg/kg 2/2 weeks and Erlotinib 150 mg oral daily (29). The treatment was usually well tolerated. At 8 weeks, 25% of patients had an objective response with SD in 61%. Another study, comparing Bevacizumab with thalidomide versus Bevacizumab alone, demonstrated similar toxicity and PFS (30).

However, the combination therapy with Bevacizumab, Erlotinib and Imatinib, did not provide additional clinical benefit and the toxicity was higher (29).

Results of two phase III trials have been published. Patients were randomized to IFN-alpha alone, IFN-alpha plus placebo or IFN-alpha with Bevacizumab (randomized open label design CALGB 90206; n = 732, and BO17705/Avoren; n = 649) (31,32). Escudier et al. recently published the results of a phase III trial. The Avoren study enrolled 649 untreated mRCC patients, to receive IFN-alpha (9 MIU subcutaneously 3x/week) and Bevacizumab (10 mg/kg q2w; n = 327) or placebo and IFN-alpha (n = 322). The study was not blinded after an interim analysis, because PFS was significantly improved in the combined group compared to IFN (10.2 months vs. 5.4 months, p = 0.0001) irrespective of risk group (32). Results of CALGB 90206 are available in abstract form. In this trial, the PFS was significantly increased in the Bevacizumab plus IFN arm compared to IFN alone (8.5 to 5.2 months; p = 0.0001). Also the combination produces more objective responses (25% vs. 13%; p = 0.0001). Data concerning overall survival are not available (31).

Finally, many other combinations are being studied with Bevacizumab and other drugs, such as high-dose IL-2 and IL-2 subcutaneous. Further combination studies are ongoing with Sorafenib, Sunitinib and temsirolimus, such as the phase II BeST trial.

**Temsirolimus - CCI-779** *(Torisel® - Wyeth Pharmaceuticals)*

CCI-779 (rapamycin-42-[2,2-bis-(hydroxy-methyl)]-propionate) is a specific inhibitor of mTOR kinase, a serine/tereonine kinase that plays a fundamental part in cell cycle regulation. The mTOR has an effector role in phosphadityl-inositol-3-kinase and Akt signaling pathways. The suppressor gene called PTEN regulates Akt and mTOR activity, whose activation, increases hypoxia inductive factor (HIF). This gene is frequently methylated in RCC (33).

In 2004, Atkins et al., reported a phase II study including 111 patients with refractory mRCC, with PR in 7%. The global clinical benefit was 51%, median PFS was 5.8 months and overall survival was 15 months with 26% of patients alive after 2 years (34). In the same year, a phase I study evaluated Temsiro-
limus in combination with IFN. The maximum dose of Temsirolimus was 15 mg/week with IFN-alpha 6 MU 3x/week. Seventy-one patients with mRCC were included and the objective response rate was 11%, while the global clinical benefit was 41% and PFS was 9.1 months (35).

In 2007, Hudes et al. published the results of the Global ARCC trial, a randomized phase III trial with 3 arms: IFN alone, IFN with Temsirolimus and Temsirolimus alone. A total of 626 patients were randomized. 67% had had a prior nephrectomy and 80% had clear cell histology. The overall survival was increased in the temsirolimus group when compared to IFN (10.9 vs. 7.4 months; p = 0.001). This study concluded that monotherapy with Temsirolimus increases overall survival in high risk patients (33). In May 2007, Temsirolimus was approved by the FDA for the treatment of mRCC. Temsirolimus is also being studied versus Sorafenib in patients who have failed first-line Sunitinib.

**Everolimus - RAD-001 (Certican® - Novartis)**

Everolimus is a rapamycin analogue and an oral mTOR inhibitor. It was studied as second-line therapy in 25 patients, with a dose of 10 mg/day in a 28 day cycle. Objective responses of 33% were obtained and side effects were mucositis, rash, hyperglycemia (36).

A placebo-controlled phase III trial investigated second-line RAD001 after failure of TKIs (RECORD-1 trial). After documented progression, patients placed initially in placebo group were able to crossover to receive everolimus. Preliminary results demonstrated that RAD-001 improved PFS over placebo in patients who previously failed TKI therapy (4.6 months vs. 1.8 months, respectively). There was no difference in terms of overall survival, perhaps due to crossover (37).

**Vatalanib - PTK787/ZK222584 (Novartis Pharmaceuticals)**

PTK787/ZK222584 is an oral inhibitor of tyrosine-kinase receptors VEGFR-1, VEGF-R-2 and PDGF-R. In phase I/II studies measurable responses in 7 of 37 patients (19%) were observed and SD was achieved in 46%, while PFS was of 5.5 months (38).

**Axitinib - AG-013736 (Pfizer)**

AG-013736 is a TK receptors inhibitor through a proven role on VEGFR-1, 2 and 3, PDGF-R-beta and c-kit by image perfusion and capillary permeability studies.

Rini et al. demonstrated anti tumoral effects of AG013746 in a phase II study that include 52 patient mRCC refractory to systemic treatment with cytokines (IL-2). The oral dose of 5 mg 2x/day was instituted until disease progression or unacceptable toxicity. No patient obtained complete response, 40% had PR and 28% SD, with a clinical benefit of 69%. The treatment was discontinued in 54% of patients however only 12% of suspension were due to side effects (39). A Phase 3 study comparing Axitinib to Sorafenib in patients who fail Sunitinib was due to commence in 2008.

**Pazopanib - GW786034 (Glaxo Smith Kline)**

Pazopanib is another oral TKI and inhibitor of VEGFR, PDGFR and c-kit. Initial studies demonstrate antitumoral activity in several tumors. In one study 3 of 3 mRCC patients showed some clinical benefit. Interim analysis of a phase II trial, analyzed the role of Pazopanib as cytokine naïve and refractory patients. Based on a consistent response rate of 27% observed after 60 treated patients, the randomization was discontinued and the study continued as a single-label, single-arm study. Drug related grade 3 or 4 adverse events were observed in 37% of the patients and 11% of the patients discontinued the treatment (40). A phase III trial is ongoing.

**Lapatinib (GSK)**

Lapatinib is an oral selective and reversible inhibitor of EGFR and ErbB2. EGFR is expressed in the majority of mRCC patients. In a phase III trial, used as second-line versus hormones the PFS was not significantly different, however, retrospectively, in selected patients, who demonstrated EGFR super-expression, the PFS was longer. The principal side effects were rash and diarrhea (41).

**Volociximab - M200 (PDL BioPharm and Biogen Idec)**

This is an immunoglobulin chimerial G4 MoAb that binds a5beta1, an integrin with a critical
role in the final pathway of tumoral proliferation and angiogenesis. In a phase II study, patients received volociximab 10 mg/Kg IV q2 weeks as a second-line therapy until progression. SD was obtained in 80% of the patients and PFS was greater than 113 days (42). It is a new promising drug and a higher dose is now being evaluated.

Other agents that play a role in the molecular regulation routes of RCC are under evaluation, some with promising pre clinical results (Figure-4).

**Bortezomib - PS-341** (*Velcade®, Millennium Pharmaceuticals*)

This is derived from boronic acid that inhibits the proteosome, stabilizing its active site by a reversible inhibition of the activity of chymotripsin-like, essential for the degradation of many intracellular proteins, such as HIF. Phase II studies investigated the use of PS-341 in mRCC. Minor clinical activity with significant toxicity, make the use of Bortezomib unlikely in the clinical setting. Other HIF inhibitors are in development (43).

**VEGF-Trap (Regeneron Pharmaceuticals)**

VEGF Trap is an inhibitor composed of VEGFR 1 and 2 parts that bind and neutralize all the VEGF-A isoforms. Six-months SD was obtained in a patient with mRCC (44).

**WX-G250 (Rencarex®, Wilex, Germany)**

eG250 is an immunoglobulin IgG1 that links to the MN antigen of the carbonic anhydrase IX found in almost 95% of RCC. Results of phase II studies, where G250 was combined with IFN-alpha and IL-2, did not show increase in toxicity, and a promising rate of SD and PR (45). A large randomized phase 3 trial of G250 in the adjuvant setting has just completed enrollment.

The great majority of anti-angiogenic trials have been designed for investigation of the clear cell subtype (Table-3). However, about 20% of RCC had a different histology and the real role of target therapies in these tumors is unclear. Specific studies for those subtypes are undergoing. A phase II trial, is investigating XL 880 (XL880® - Exelisis)
### Table 3 – Systemic therapies for metastatic renal cell carcinoma.

<table>
<thead>
<tr>
<th>N. of Patients</th>
<th>Phase Trial</th>
<th>Objective Response Rate, (CR+PR)%</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>1347</td>
<td>II 51 trials 5</td>
<td>Motzer et al., 2000. (14)</td>
</tr>
<tr>
<td>IFN-alpha†</td>
<td>963</td>
<td>II 6 trials 12</td>
<td>Coppin et al., 2005. (15)</td>
</tr>
<tr>
<td>High-dose IL-2*†</td>
<td>255</td>
<td>II 23 trials 14</td>
<td>Fyfe et al., 1995. (47)</td>
</tr>
<tr>
<td>IFN-alpha plus IL-2</td>
<td>607</td>
<td>II 23 trials 19</td>
<td>Vogelzang et al., 1993. (48)</td>
</tr>
<tr>
<td>IFN-alpha + cytoreduction EORTC 30947</td>
<td>42</td>
<td>III 23 trials 19 vs. 12</td>
<td>Mickisch et al., 2001. (6)</td>
</tr>
<tr>
<td>Sorafenib* ‡</td>
<td>903</td>
<td>III 23 trials 10 vs. 2 (SD 74%)</td>
<td>Escudier et al., 2007. (25)</td>
</tr>
<tr>
<td>Sorafenib plus IFN-alpha</td>
<td>62</td>
<td>II 23 trials 19 (SD 50%)</td>
<td>Ryan et al., 2007. (27)</td>
</tr>
<tr>
<td>Sunitinib* ‡</td>
<td>750</td>
<td>III 23 trials 31 vs. 6</td>
<td>Motzer et al., 2007. (22)</td>
</tr>
<tr>
<td>Temsirolimus* †</td>
<td>626</td>
<td>III 23 trials 9 vs. 7 (SD 63 vs. 32%)*</td>
<td>Hudes et al., 2007. (33)</td>
</tr>
<tr>
<td>Everolimus</td>
<td>25</td>
<td>II 23 trials 33</td>
<td>Amato et al., 2006. (36)</td>
</tr>
<tr>
<td>Everolimus</td>
<td>410</td>
<td>III 23 trials 1 (SD 63 vs. 32%)*</td>
<td>Motzer et al., 2008. (37)</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>116</td>
<td>II 23 trials 10</td>
<td>Yang et al., 2003. (28)</td>
</tr>
<tr>
<td>Bevacizumab + IFN-alpha †</td>
<td>649</td>
<td>III 23 trials 31 vs. 13</td>
<td>Escudier et al., 2007. (32)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>225</td>
<td>II 23 trials 30 (SD 73%)*</td>
<td>Hutson et al., 2007. (40)</td>
</tr>
<tr>
<td>Axitinib</td>
<td>52</td>
<td>II 23 trials 40</td>
<td>Rini et al., 2005. (39)</td>
</tr>
<tr>
<td>Voluticiximab</td>
<td>40</td>
<td>II 23 trials - (SD 87%)</td>
<td>Figlin et al., 2006. (42)</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>37</td>
<td>II 23 trials 11</td>
<td>Kondagunata et al., 2004. (43)</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>21</td>
<td>II 23 trials No</td>
<td>Dawson et al., 2004. (49)</td>
</tr>
</tbody>
</table>

* = drugs approved by FDA (USA Food and Drugs Administration); † = drugs approved by EMEA (European Medicines Agency); ‡ = interim analysis; CR = complete response; PR = partial response; SD = stable disease
Metastatic Renal Cell Carcinoma Management

in papillary renal cell carcinoma. XL 880 is a potent dual TK receptor inhibitor, the primary targets of which are VEGFR2 and MET receptors. Hereditary and sporadic papillary RCC have in common MET over-expression or mutation. Interim data have been reported and 6-months SD was achieved in 12/16 patients (46).

Concerning sequential and combination therapy, efforts should be made to clarify several clinical issues regarding the optimal use of these drugs, specially the possibility of cross-resistance to agents acting against the same targets. Clinically, resistance to anti-angiogenic agents has been described. To date, mechanisms of resistance and other issues of chronic anti-angiogenic use remains largely unclear. In vitro studies have suggested that mutations of TK receptors could be responsible for molecular resistance.

CONCLUSIONS

For years, the major progress in the management of renal cell carcinoma has been achieved in localized disease. Relevant advances in molecular biology permit the development of new drugs to treat metastatic patients. The usefulness of nephrectomy as neoadjuvant therapy in mRCC was confirmed in the cytokine era and surgical resection of metastases had a positive impact on prognosis, however if nephrectomy remains an integral part of mRCC management in this new era is unknown.

Analysis of the most recent clinical data recommended Sunitinib as first-line treatment for favorable and intermediate risk profile. Similarly, Bevacizumab given in combination with IFN-alpha demonstrated benefit and is an alternative option. Temsirolimus showed efficacy in patients stratified into poor risk group (≥ 3 risk factors) and should be considered an option for first-line use in this group. To date, IL-2 might be an alternative treatment for a select good risk group with clear-cell histology. Sorafenib is recommended for mRCC after failure of prior systemic first-line strategies.

The results from new targeted therapy trials give much cause for encouragement in the treatment of mRCC, and are fast becoming the new standard of care.

It is imperative that urologists and clinical oncologists work together, participating in trials to answer further pressing questions. What is the standard regime? Should monotherapy or combinations be used? What is the optimal dose and schedule? What are the treatment options for non-clear cell subtypes? What is the role of neoadjuvant therapy, by cytoreductive surgery or systemic therapies? In the area of adjuvant therapy, drugs that act on pathways of cellular proliferation may have a role. New drugs are being developed and used in clinical trials, in combination or as single agents, and show promising preliminary results. Future analysis of biomarkers may well provide data to aid in the selection of subgroups and define follow-up strategies in mRCC.

ACKNOWLEDGEMENTS

Dr. Ernani Rhoden, Department of Urology, Federal Faculty of Medical Sciences, critical review this manuscript.

CONFLICT OF INTEREST

Dr. Escudier receives consulting fees and lecture fees from Roche, Bayer, Wyeth, Pfizer, Inate, and Antigenics. Dr. Guy Vallancien is a study investigator of Sanofi-Aventis.

REFERENCES


Metastatic Renal Cell Carcinoma Management


Accepted after revision: December 5, 2008

Correspondence address:
Dr. Flavio Lobo Heldwein
Altamiro Guimaraes, 360 / 504
Florianopolis, SC, 88015-510, Brazil
Fax: + 55 48 3223-0816
E-mail: flavio.lobo@gmail.com